Disease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse event.
Marshall
R W
RW
Marshall
V J
VJ
Hull
R
R
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000009:adverse effects; D005260:Female; D006801:Humans; D064747:Lansoprazole; D008727:Methotrexate / Q000009:adverse effects; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives; D010198:Pancytopenia / Q000139:chemically induced*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000890:Anti-Infective Agents; D018501:Antirheumatic Agents; D064747:Lansoprazole; D009853:Omeprazole; D001241:Aspirin; D008727:Methotrexate